Business Wire

MA-IMMUTA

20.5.2021 15:02:06 CEST | Business Wire | Press release

Share
Immuta Announces $90 Million in Series D Funding

Immuta , the leading provider of cloud data access control, today announced that it has secured $90 million in Series D funding. Immuta will use the investment to further its market leadership position and capture rising demand for centralized, scalable access control across cloud data sets that are increasingly diverse and distributed on multiple compute platforms. The new investment comes less than a year after Immuta’s Series C investment and brings total capital raised to $169 million.

The Series D funding round includes new investors Greenspring Associates, March Capital, NGP Capital, and Wipro Ventures, as well as participation from existing investors Ten Eleven Ventures, Intel Capital, DFJ Growth, Dell Technologies Capital, Citi Ventures, and Okta Ventures. The investment will go towards accelerating Immuta’s product research and development, expanding sales and marketing capacity to capture growing demand in the U.S., EMEA, and APAC, and deepening strategic partnerships within the cloud data ecosystem. Amazon Redshift and Azure Synapse are the latest cloud data platforms to be integrated with Immuta’s platform as part of its latest release announced today .

“We’ve entered a new era in data and analytics fueled by ubiquitous cloud storage, new cloud data management tools, and the rise of DataOps,” said Immuta’s CEO Matthew Carroll. “In this new environment, data teams are challenged to provide secure, scaled access to thousands of cloud data products while maintaining strong security, privacy protection, and auditability. Traditional methods of data access control don’t work, don’t scale across cloud compute platforms, and can limit data utility. Immuta’s platform solves this problem elegantly without requiring data to be moved, copied, or manually provisioned. This new funding will accelerate innovation and GTM expansion so we can deliver our platform to more customers as we lead the charge to define the future of cloud data access control.”

“We looked at other competition in the space and Immuta’s product and solutions are really at the top of the heap,” said Hunter Somerville, General Partner at Greenspring Associates. From intelligent data discovery, to data access and control, to integration with all the top cloud analytics services, Immuta’s platform is best-in-class. We also liked that Immuta prioritized the data architecture and engineering team, from an end-sales standpoint, which we didn't see from other solutions in the space.”

“We invest in tomorrow’s winners,” said Jed Leidheiser, Partner at March Capital. “I look for companies that have tremendous customer satisfaction today, with architectures built for platform expansion, and an A+ team to execute. That’s Immuta. They have the ability to operate on any data source, any infrastructure, any cloud platform — and on top of that, their customer list is rapidly growing.”

Since its founding in 2015, Immuta has built strategic partnerships with the leading cloud data technology providers and enhanced its platform to provide a single place for data teams to automate data across control across their entire cloud infrastructure. As the market leader, Immuta helps large enterprises scale centralized data operations and analytics teams and helps innovative technology companies build and scale data-powered apps and services. In its last fiscal year, Immuta grew worldwide bookings by more than 115%, doubled its full-time headcount, and expanded its global base of customers including Aon, Credit Suisse, Daimler, Flatiron, IAG, S&P Global, and US Army.

"Immuta has been a longtime partner of Databricks and we are excited to see this impressive round of funding. We look forward to helping bring their cloud data access control capabilities to more joint customers as they're building their future data and analytics stack on the lakehouse platform," said Ali Ghodsi, CEO and co-founder of Databricks.

“One of the really big advantages that Immuta has given us, from a return-on-investment perspective, is our ability to make change happen faster,” said Dave Abrahams, Executive

General Manager of Data, IAG, one of Australia and New Zealand’s largest general insurance providers and an Immuta investor. “Previously, it would take months of manual assessments, and working through the challenges around how we could access and use data to help create the best products for our customers. We are now able to do that in an instant, globally, across all of our data.”

For more information about Immuta, visit www.immuta.com . Join the Immuta conversation on LinkedIn and Twitter .

About Immuta

Immuta is the market leader in cloud data access control, providing data engineering and operations teams one universal platform to control access to analytical data sets in the cloud. Only Immuta can automate access control for any data, on any cloud service, across all compute infrastructure. Data-driven organizations around the world rely on Immuta to speed time to data, safely share more data with more users, and mitigate the risk of data leaks and breaches. Founded in 2015, Immuta is headquartered in Boston, MA. Learn more at www.immuta.com .

About Greenspring

Greenspring Associates was founded in 2000 to focus solely on venture capital investments. Through a comprehensive platform, the Firm serves as a lifecycle partner for fund managers and entrepreneurs, investing across multiple stages, sectors and geographies. Greenspring Associates currently manages over $12 billion in committed capital across a variety of specialized venture strategies on behalf of a diverse group of global investors. For more information on Greenspring Associates, please visit its website at www.greenspringassociates.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye